Boehringer Ingelheim defends antitrust litigation involving Mirapex® patents
Clients Boehringer Ingelheim GmbH
Jones Day represented Boehringer Ingelheim GmbH as antitrust defense counsel in litigation brought by the generic drug manufacturer Mylan claiming that Boehringer Ingelheim wrongfully enforced patents against Mylan for its drug Mirapex® to exclude generic competition from the market in violation of Sections 1 and 2 of the Sherman Act. Additional follow on class actions were brought against Boehringer Ingelheim by direct and indirect purchasers of Mirapex® asserting substantially similar antitrust claims. All plaintiffs voluntarily dismissed their complaints.
Mylan Inc. et al. v. Boehringer Ingelheim International GmbH, et al., No. 09-990 (W.D. Pa., filed July 2009)